Hbm climbs on progress of AstraZeneca collaboration

** Shares of Hbm Holdings climb 2.3% to HK$13.2, on course for the biggest one-day pct gain since Nov 14** Hbm said the scope of collaboration with AstraZeneca was further advanced following an amendment to an earlier agreement, aiming to develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers** The therapeutics developer for immuno-oncology and immunology diseases said the economic terms remain consistent with the financial framework established under the agreement ** YTD, stock up 590%, Hang Seng Biotech Index (.HSBIO) up 77.2%